Company news
Connect Biopharma Holdings Limited news in 2023
Connect Biopharma Holdings Limited's news releases, calls and decks from 2023, newest first.
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
December 11, 2023
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
December 10, 2023
Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart
November 22, 2023
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
November 20, 2023
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
November 20, 2023
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
September 11, 2023
Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis
May 31, 2023
Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update
April 10, 2023
Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms
March 17, 2023
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions
March 16, 2023
Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting
March 5, 2023
Decks in 2023
- Investor Presentation (June 2023)
Investor deck · 40 slides · Jun 5, 2023
- Technical Presentation (March 2023)
Technical · 5 slides · March 2023